Market Authorisation Date: 22 December, 2015

Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion; Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy; Treatment of patients with locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil; Use in combination with doxorubicin and cyclophosphamide for adjuvant treatment of patients with operable node-positive breast cancer; Treatment of patients with locally advanced metastatic breast cancer after failure of prior chemotherapy; Use in combination with cisplatin for treatment of unresectable, locally advanced or metastatic non-small cell lung cancer without prior chemotherapy treatment; Treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer in combination with prednisone; Treatment of advanced gastric adenocarcinoma in combination with cisplatin and fluorouracil in patients that have not received prior chemotherapy; Method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution

Dosage: INJECTABLE;INJECTION